Webb N, et al. - An inquiry was set up with regard to the relative efficacy and safety of semaglutide once-weekly (QW) vs glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) in Japanese patients with type 2 diabetes (T2DM), with emphasis on the comparison between semaglutide 0.5 mg QW and dulaglutide 0.75 mg QW. Semaglutide 0.5 mg QW exhibited significant reductions from baseline in glycated hemoglobin (HbA_1c), weight, systolic blood pressure (SBP) and fasting plasma glucose (FPG) compared with dulaglutide 0.75 mg QW in the study cohort. Yielded results could present valuable evidence for clinical decision-making, cost-effectiveness analyses, and health technology appraisal (HTA) requirements.